Spain (ES)

Die Konzeption von Erfolg aus Sicht von Absolvent:innen mit Beeinträchtigung: Schlüsselaspekte der Inklusion in der deutschen Hochschulbildung (2024) Lopez-Gavira R, Orozco I, Angerhausen P Journal article, Original article Immunological and molecular features of the tumor microenvironment of long-term survivors of ovarian cancer (2024) Nelson BH, Hamilton P, Phung MT, Milne K, Harris B, Thornton S, Stevens D, et al. Journal article Plasticity of 3D Hydrogels Predicts Cell Biological Behavior (2024) Malandrino A, Zhang H, Schwarm N, Böhringer D, Kah DTE, Kuster C, Boccaccini AR, Fabry B Journal article Model-driven exploration of poro-viscoelasticity in human brain tissue: be careful with the parameters! (2024) Greiner A, Reiter N, Hinrichsen J, Kainz MP, Sommer G, Holzapfel GA, Steinmann P, et al. Journal article Data-driven modelling of hydraulic-head time series: results and lessons learned from the 2022 Groundwater Time Series Modelling Challenge (2024) Collenteur RA, Haaf E, Bakker M, Liesch T, Wunsch A, Soonthornrangsan J, White J, et al. Journal article The EDELIFE clinical trial, the first investigation of a signalling molecule to treat in utero a human developmental genetic disorder (2024) Schneider H, Hadj-Rabia S, Faschingbauer F, Bodemer C, Grange DK, Guillén-Navarro E, Tadini G, Clarke A Journal article, Original article Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial (2024) Harbeck N, Ciruelos E, Jerusalem G, Müller V, Niikura N, Viale G, Bartsch R, et al. Journal article Early photometric and spectroscopic observations of the extraordinarily bright INTEGRAL-detected GRB 221009A (2024) Sánchez-Ramírez R, Guedes Lang R, Pozanenko A, Martínez-Huerta H, Hu YD, Pandey SB, Gupta R, et al. Journal article A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study (2024) Neven P, Stahl N, Vidal M, Martín M, Kaufman PA, Harbeck N, Hunt KK, et al. Journal article Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy (2024) Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TA, Fenk R, et al. Journal article